Briefs

Miners’ Efforts to Attract More Female Workers Fall Flat

The mining industry’s efforts to hire and retain more women have fallen flat in one of the world’s most male-dominated sectors.

Read More →

Consumer Prices Jumped 5 Percent in May From Year Earlier, Faster Than Expected

Consumer prices have risen at the fastest annual rate since 2008, causing some economists to worry even more about inflation.

Read More →

Shell to Speed Up Energy Transition Plan After Dutch Court Ruling

After a ruling by a district court in The Hague said that Shell must cut its net carbon emissions by 45% by 2030, the company announced that it will in fact accelerate its plan to cut emissions.

Read More →

Apple’s Moves to Tighten Flow of User Data Leave Advertisers Anxious

Digital advertising companies say that Apple’s new user data rules will drastically impact their business strategy and their bottom line.

Read More →

The World’s Biggest Investors Get Louder About ESG

Managers for some of the world’s largest funds have been more vocal about voting in favor of ESG policies at shareholder meetings.

Read More →

Biden Administration Pushes Domestic Pharmaceutical Production

The Biden administration hopes to boost U.S.-based pharmaceutical production as part of its plan to shore up the supply chain.

Read More →

Medline Buyout May Set Off Private Equity Investment Wave

Experts say that the recent buyout of medical supply company Medline signals the next wave of private equity investment in healthcare.

Read More →

Internet Outage Hits Major Websites

Thousands of websites experienced outages for roughly an hour this week due to an internal glitch at Fastly, a major cloud-services provider.

Read More →

Carmakers Try to Spark US Love Affair with Electric Pick-Up Trucks

Car manufacturers are hoping that the U.S. love of pick-up trucks will translate over to electric ones, with many big companies such as Rivian and Ford unveiling brand new electric models.

Read More →

Biogen’s $56,000-a-Year Alzheimer’s Drug Reignites US Debate Over Costs

The approval of Biogen’s new Alzheimer’s treatment has reignited U.S. debate over the high cost of drugs in the world’s largest and most profitable healthcare market.

Read More →